Market Access BIO Boston: 2025 is shaping up to be a year of challenge – b... What were the major themes to come out of BIO Boston 2025? Despite global events in the background, a fair amount of positivity.
R&D GRIN Therapeutics: Seeking to address unmet needs in rare ne... Dr Bruce Leuchter, CEO of GRIN Therapeutics and Neurvati Neurosciences, discusses the companies GRIN-NDD work with pharmaphorum.
News INmune Bio slumps on midstage fail for Alzheimer's drug INmune Bio's bid to develop an Alzheimer's drug with a new mechanism of action has been dented, but the company remains upbeat.
News Biogen races into phase 3 with Spinraza follow-up Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.
News Welsh biotech Draig emerges with $140m in financing Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.
News NewAmsterdam says lead drug may have Alzheimer's role NewAmsterdam has said that an oral drug it is developing to lower cholesterol has shown early efficacy as a preventive therapy for Alzheimer's.
News Takeda's narcolepsy programme gets back on track Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face